Nuvation Bio Inc. (NUVB)
Bid | 1.95 |
Market Cap | 663.26M |
Revenue (ttm) | 10.96M |
Net Income (ttm) | -606.38M |
EPS (ttm) | -2.2 |
PE Ratio (ttm) | -0.89 |
Forward PE | -3.33 |
Analyst | Buy |
Ask | 1.99 |
Volume | 7,425,267 |
Avg. Volume (20D) | 5,340,943 |
Open | 1.98 |
Previous Close | 1.93 |
Day's Range | 1.95 - 2.10 |
52-Week Range | 1.54 - 3.97 |
Beta | 1.37 |
About NUVB
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for NUVB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription

2 weeks ago · https://www.defenseworld.net
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $925,000 Holdings in Nuvation Bio Inc. (NYSE:NUVB)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Nuvation Bio Inc. (NYSE:NUVB – Free Report) by 54.2% in the 4th quarter, according to the company in i...

1 month ago · seekingalpha.com
Nuvation Bio: A Real Shot To Move The Needle In Lung Cancer SubtypesNuvation Bio's taletrectinib shows strong efficacy in ROS1-positive NSCLC, with a 90.1% response rate, and FDA approval is likely by June 2025. Financially robust, Nuvation Bio has over three years of...

2 months ago · businesswire.com
Nuvation Bio to Present at The Citizens Life Sciences ConferenceNEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, today announced that Philippe Sauvage, Chief Financia...